ALS biomarkers for therapy development: State of the field and future directions-Reference-Cited by-同舟云学术

ALS biomarkers for therapy development: State of the field and future directions

Published:2015-12-29 Issue:2 Volume:53 Page:169-182
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Benatar Michael¹,Boylan Kevin²,Jeromin Andreas³,Rutkove Seward B.⁴,Berry James⁵,Atassi Nazem⁵,Bruijn Lucie⁶

Affiliation:

1. Department of Neurology; University of Miami; Miami Florida USA 33136

2. Department of Neurology; Mayo Clinic Jacksonville; Jacksonville Florida USA

3. Iron Horse Diagnostics; Scottsdale Arizona USA

4. Department of Neurology; Beth Israel Deaconess Medical Center; Boston Massachusetts USA

5. Department of Neurology; Massachusetts General Hospital; Boston Massachusetts USA

6. ALS Association; Washington DC USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Reference116 articles.

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Biomarkers Definitions Working Group;Clin Pharmacol Ther,2001

2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry and FDA staff: qualification process for drug development Tools2014 Washington, DC CDER

3. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis;Shepheard;PLoS One,2014

4. Biomarkers and surrogate markers: an FDA perspective;Katz;NeuroRx,2004

5. The PRO-ACT database: design, initial analyses, and predictive features;Atassi;Neurology,2014

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice;Annals of Neurology;2023-12-28

2. Nerve excitability measured with the TROND protocol in amyotrophic lateral sclerosis: a systematic review and meta-analysis;Journal of Neurophysiology;2023-12-01

3. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis;BMJ;2023-10-27

4. Skeletal muscle as a molecular and cellular biomarker of disease progression in amyotrophic lateral sclerosis: a narrative review;Neural Regeneration Research;2023-08-14

5. Far‐field potential of the compound muscle action potential as a reliable marker in amyotrophic lateral sclerosis;Muscle & Nerve;2023-04-22